Inflammatory Bowel Disease. Historical Perspective, Epidemiology, and Risk Factors.

Surgical Clinics of North America

Volumn 95, Issue 6, 2015, Pages 1105-1122

  Malik, Talha A ^a,b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Crohn's disease; Epidemiology; Historical perspective; Inflammatory bowel disease; Risk factors; Ulcerative colitis

Indexed keywords

AGE DISTRIBUTION; BREAST FEEDING; DISEASE ASSOCIATION; DISEASE COURSE; ENVIRONMENTAL FACTOR; GENETIC PREDISPOSITION; HUMAN; HYGIENE; IMMUNE RESPONSE; IMMUNIZATION; INCIDENCE; INFECTION; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; MALIGNANT NEOPLASTIC DISEASE; MESENTERIC FAT; MORTALITY; OBESITY; OUTCOME ASSESSMENT; PATHOGENESIS; PREGNANCY; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SMOKING; SURGICAL RISK; TREND STUDY; INFLAMMATORY BOWEL DISEASES;

HUMANS; INFLAMMATORY BOWEL DISEASES; RISK FACTORS;

EID: 84940927198     PISSN: 00396109     EISSN: 15583171     Source Type: Journal    
DOI: 10.1016/j.suc.2015.07.006     Document Type: Review

References (130)

1. Ananthakrishnan A.N. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol 2015, 12:205-217.
2. Burisch J., Munkholm P. The epidemiology of inflammatory bowel disease. Scand J Gastroenterol 2015, 50(8):942-951.
3. Cosnes J., Gower-Rousseau C., Seksik P., et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011, 140(6):1785-1794.
4. Abraham C., Cho J.H. Inflammatory bowel disease. N Engl J Med 2009, 361(21):2066-2078.
5. Loftus E.V. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004, 126(6):1504-1517.
6. Malik T., Mannon P. Inflammatory bowel diseases: emerging therapies and promising molecular targets. Front Biosci 2012, 4:1172-1189.
7. Kirsner J.B. Historical aspects of inflammatory bowel disease. J Clin Gastroenterol 1988, 10(3):286-297.
8. Kirsner J.B. Historical origins of current IBD concepts. World J Gastroenterol 2001, 7(2):175-184.
9. Crohn B.B., Ginzburg L., Oppenheimer G.D. Landmark article Oct 15, 1932. Regional ileitis. A pathological and clinical entity. By Burril B. Crohn, Leon Ginzburg, and Gordon D. Oppenheimer. JAMA 1984, 251(1):73-79.
10. Ginzburg L. X-ray diagnosis of acute intestinal obstruction without the use of contrast media. Ann Surg 1932, 96(3):368-380.
11. Targan S.R., Hanauer S.B., van Deventer S.J., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997, 337(15):1029-1035.
12. Present D.H., Rutgeerts P., Targan S., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999, 340(18):1398-1405.
13. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359(9317):1541-1549.
14. Sands B.E., Anderson F.H., Bernstein C.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004, 350(9):876-885.
15. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353(23):2462-2476.
16. Sandborn W.J., Feagan B.G., Stoinov S., et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007, 357(3):228-238.
17. Podolsky D.K. Inflammatory bowel disease. N Engl J Med 2002, 347(6):417-429.
18. Sood A., Midha V. Epidemiology of inflammatory bowel disease in Asia. Indian J Gastroenterol 2007, 26(6):285-289.
19. Archampong T.N., Nkrumah K.N. Inflammatory bowel disease in Accra: what new trends. West Afr J Med 2013, 32(1):40-44.
20. Ukwenya A.Y., Ahmed A., Odigie V.I., et al. Inflammatory bowel disease in Nigerians: still a rare diagnosis?. Ann Afr Med 2011, 10(2):175-179.
21. Gasche C., Scholmerich J., Brynskov J., et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000, 6(1):8-15.
22. Silverberg M.S., Satsangi J., Ahmad T., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005, 19(Suppl A):5A-36A.
23. Dressel U., Allen T.L., Pippal J.B., et al. The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol Endocrinol 2003, 17(12):2477-2493.
24. Thia K.T., Sandborn W.J., Harmsen W.S., et al. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 2010, 139(4):1147-1155.
25. Munkholm P., Langholz E., Davidsen M., et al. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995, 30(7):699-706.
26. Bengtson M.B., Solberg C., Aamodt G., et al. Clustering in time of familial IBD separates ulcerative colitis from Crohn's disease. Inflamm Bowel Dis 2009, 15(12):1867-1874.
27. Solberg I.C., Lygren I., Jahnsen J., et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009, 44(4):431-440.
28. Langholz E., Munkholm P., Davidsen M., et al. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994, 107(1):3-11.
29. Sands B.E. Inflammatory bowel disease: past, present, and future. J Gastroenterol 2007, 42(1):16-25.
30. Molodecky N.A., Soon I.S., Rabi D.M., et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012, 142(1):46-54.e42. [quiz: e30].
31. Kurata J.H., Kantor-Fish S., Frankl H., et al. Crohn's disease among ethnic groups in a large health maintenance organization. Gastroenterology 1992, 102:1940-1948.
32. Bernstein C.N., Wajda A., Svenson L.W., et al. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol 2006, 101(7):1559-1568.
33. Pinchbeck B.R., Kirdeikis J., Thomson A.B. Inflammatory bowel disease in northern Alberta. An epidemiologic study. J Clin Gastroenterol 1988, 10(5):505-515.
34. Vind I., Riis L., Jess T., et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol 2006, 101(6):1274-1282.
35. Langholz E., Munkholm P., Nielsen O.H., et al. Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987. Scand J Gastroenterol 1991, 26(12):1247-1256.
36. Moum B., Vatn M.H., Ekbom A., et al. Incidence of ulcerative colitis and indeterminate colitis in four counties of southeastern Norway, 1990-93. A prospective population-based study. The Inflammatory Bowel South-Eastern Norway (IBSEN) Study Group of Gastroenterologists. Scand J Gastroenterol 1996, 31(4):362-366.
37. Loftus E.V., Silverstein M.D., Sandborn W.J., et al. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology 1998, 114(6):1161-1168.
38. Loftus E.V., Silverstein M.D., Sandborn W.J., et al. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut 2000, 46(3):336-343.
39. Bernstein C.N., Rawsthorne P., Cheang M., et al. A population-based case control study of potential risk factors for IBD. Am J Gastroenterol 2006, 101(5):993-1002.
40. Devlin H.B., Datta D., Dellipiani A.W. The incidence and prevalence of inflammatory bowel disease in North Tees Health District. World J Surg 1980, 4(2):183-193.
41. Auvin S., Molinie F., Gower-Rousseau C., et al. Incidence, clinical presentation and location at diagnosis of pediatric inflammatory bowel disease: a prospective population-based study in northern France (1988-1999). J Pediatr Gastroenterol Nutr 2005, 41(1):49-55.
42. Mendeloff A.I., Monk M., Siegel C.I., et al. Some epidemiological features of ulcerative colitis and regional enteritis. A preliminary report. Gastroenterology 1966, 51(5):748-756.
43. Ogunbi S.O., Ransom J.A., Sullivan K., et al. Inflammatory bowel disease in African-American children living in Georgia. J Pediatr 1998, 133:103-107.
44. Goldman C.D., Kodner I.J., Fry R.D., et al. Clinical and operative experience with non-Caucasian patients with Crohn's disease. Dis Colon Rectum 1986, 29(5):317-321.
45. Straus W.L., Eisen G.M., Sandler R.S., et al. Crohn's disease: does race matter? The Mid-Atlantic Crohn's Disease Study Group. Am J Gastroenterol 2000, 95(2):479-483.
46. Mahid S.S., Mulhall A.M., Gholson R.D., et al. Inflammatory bowel disease and African Americans: a systematic review. Inflamm Bowel Dis 2008, 14(7):960-967.
47. Karban A., Waterman M., Panhuysen C.I., et al. NOD2/CARD15 genotype and phenotype differences between Ashkenazi and Sephardic Jews with Crohn's disease. Am J Gastroenterol 2004, 99(6):1134-1140.
48. Yang H., McElree C., Roth M.P., et al. Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews. Gut 1993, 34(4):517-524.
49. Halme L., Paavola-Sakki P., Turunen U., et al. Family and twin studies in inflammatory bowel disease. World J Gastroenterol 2006, 12(23):3668-3672.
50. Kostic A.D., Xavier R.J., Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 2014, 146(6):1489-1499.
51. Jostins L., Ripke S., Weersma R.K., et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012, 491(7422):119-124.
52. Nagalingam N.A., Lynch S.V. Role of the microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 2012, 18(5):968-984.
53. Darfeuille-Michaud A., Boudeau J., Bulois P., et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004, 127(2):412-421.
54. Martini G.A., Brandes J.W. Increased consumption of refined carbohydrates in patients with Crohn's disease. Klin Wochenschr 1976, 54(8):367-371.
55. Thornton J.R., Emmett P.M., Heaton K.W. Diet and Crohn's disease: characteristics of the pre-illness diet. Br Med J 1979, 2(6193):762-764.
56. Asakura H., Suzuki K., Kitahora T., et al. Is there a link between food and intestinal microbes and the occurrence of Crohn's disease and ulcerative colitis?. J Gastroenterol Hepatol 2008, 23(12):1794-1801.
57. Bedford P.A., Todorovic V., Westcott E.D., et al. Adipose tissue of human omentum is a major source of dendritic cells, which lose MHC Class II and stimulatory function in Crohn's disease. J Leukoc Biol 2006, 80(3):546-554.
58. Geerling B.J., v Houwelingen A.C., Badart-Smook A., et al. Fat intake and fatty acid profile in plasma phospholipids and adipose tissue in patients with Crohn's disease, compared with controls. Am J Gastroenterol 1999, 94(2):410-417.
59. Karmiris K., Koutroubakis I.E., Kouroumalis E.A. Leptin, adiponectin, resistin, and ghrelin-implications for inflammatory bowel disease. Mol Nutr Food Res 2008, 52(8):855-866.
60. Yamamoto K., Kiyohara T., Murayama Y., et al. Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn's disease. Gut 2005, 54(6):789-796.
61. Blain A., Cattan S., Beaugerie L., et al. Crohn's disease clinical course and severity in obese patients. Clin Nutr 2002, 21(1):51-57.
62. Hass D.J., Brensinger C.M., Lewis J.D., et al. The impact of increased body mass index on the clinical course of Crohn's disease. Clin Gastroenterol Hepatol 2006, 4(4):482-488.
63. Harries A.D., Baird A., Rhodes J. Non-smoking: a feature of ulcerative colitis. Br Med J 1982, 284(6317):706.
64. Cosnes J. Crohn's disease phenotype, prognosis, and long-term complications: what to expect?. Acta Gastroenterol Belg 2008, 71(3):303-307.
65. Cosnes J., Nion-Larmurier I., Afchain P., et al. Gender differences in the response of colitis to smoking. Clin Gastroenterol Hepatol 2004, 2(1):41-48.
66. Lakatos P.L., Szamosi T., Lakatos L. Smoking in inflammatory bowel diseases: good, bad or ugly?. World J Gastroenterol 2007, 13(46):6134-6139.
67. Higuchi L.M., Khalili H., Chan A.T., et al. A prospective study of cigarette smoking and the risk of inflammatory bowel disease in women. Am J Gastroenterol 2012, 107(9):1399-1406.
68. Cosnes J., Carbonnel F., Beaugerie L., et al. Effects of cigarette smoking on the long-term course of Crohn's disease. Gastroenterology 1996, 110(2):424-431.
69. Cosnes J., Carbonnel F., Carrat F., et al. Effects of current and former cigarette smoking on the clinical course of Crohn's disease. Aliment Pharmacol Ther 1999, 13(11):1403-1411.
70. Biedermann L., Brulisauer K., Zeitz J., et al. Smoking cessation alters intestinal microbiota: insights from quantitative investigations on human fecal samples using FISH. Inflamm Bowel Dis 2014, 20(9):1496-1501.
71. Persson P.G., Hellers G., Ahlbom A. Use of oral moist snuff and inflammatory bowel disease. Int J Epidemiol 1993, 22(6):1101-1103.
72. Shaw S.Y., Blanchard J.F., Bernstein C.N. Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol 2010, 105(12):2687-2692.
73. Chan S.S., Luben R., Bergmann M.M., et al. Aspirin in the aetiology of Crohn's disease and ulcerative colitis: a European prospective cohort study. Aliment Pharmacol Ther 2011, 34(6):649-655.
74. Ananthakrishnan A.N., Higuchi L.M., Huang E.S., et al. Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study. Ann Intern Med 2012, 156(5):350-359.
75. Cornish J.A., Tan E., Simillis C., et al. The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis. Am J Gastroenterol 2008, 103(9):2394-2400.
76. Khalili H., Higuchi L.M., Ananthakrishnan A.N., et al. Hormone therapy increases risk of ulcerative colitis but not Crohn's disease. Gastroenterology 2012, 143(5):1199-1206.
77. Khalili H., Higuchi L.M., Ananthakrishnan A.N., et al. Oral contraceptives, reproductive factors and risk of inflammatory bowel disease. Gut 2013, 62(8):1153-1159.
78. Aamodt G., Bukholm G., Jahnsen J., et al. The association between water supply and inflammatory bowel disease based on a 1990-1993 cohort study in southeastern Norway. Am J Epidemiol 2008, 168(9):1065-1072.
79. Bernstein C.N., Blanchard J.F., Rawsthorne P., et al. Population-based case control study of seroprevalence of Mycobacterium paratuberculosis in patients with Crohn's disease and ulcerative colitis. J Clin Microbiol 2004, 42(3):1129-1135.
80. Selby W., Pavli P., Crotty B., et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 2007, 132(7):2313-2319.
81. Gradel K.O., Nielsen H.L., Schonheyder H.C., et al. Increased short- and long-term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis. Gastroenterology 2009, 137(2):495-501.
82. Thompson N.P., Montgomery S.M., Pounder R.E., et al. Is measles vaccination a risk factor for inflammatory bowel disease?. Lancet 1995, 345(8957):1071-1074.
83. Bernstein C.N., Rawsthorne P., Blanchard J.F. Population-based case-control study of measles, mumps, and rubella and inflammatory bowel disease. Inflamm Bowel Dis 2007, 13(6):759-762.
84. Davis R.L., Kramarz P., Bohlke K., et al. Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease: a case-control study from the Vaccine Safety Datalink project. Arch Pediatr Adolesc Med 2001, 155(3):354-359.
85. Ananthakrishnan A.N., Issa M., Binion D.G. Clostridium difficile and inflammatory bowel disease. Gastroenterol Clin North Am 2009, 38(4):711-728.
86. Singh S., Graff L.A., Bernstein C.N. Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD?. Am J Gastroenterol 2009, 104(5):1298-1313. [quiz: 1314].
87. Feeney M., Ciegg A., Winwood P., et al. A case-control study of measles vaccination and inflammatory bowel disease. The East Dorset Gastroenterology Group. Lancet 1997, 350(9080):764-766.
88. Morris D.L., Montgomery S.M., Thompson N.P., et al. Measles vaccination and inflammatory bowel disease: a national British Cohort Study. Am J Gastroenterol 2000, 95(12):3507-3512.
89. Strachan D.P. Hay fever, hygiene, and household size. BMJ 1989, 299(6710):1259-1260.
90. Timm S., Svanes C., Janson C., et al. Place of upbringing in early childhood as related to inflammatory bowel diseases in adulthood: a population-based cohort study in Northern Europe. Eur J Epidemiol 2014, 29(6):429-437.
91. Radon K., Windstetter D., Poluda A.L., et al. Contact with farm animals in early life and juvenile inflammatory bowel disease: a case-control study. Pediatrics 2007, 120(2):354-361.
92. Van Kruiningen H.J., Joossens M., Vermeire S., et al. Environmental factors in familial Crohn's disease in Belgium. Inflamm Bowel Dis 2005, 11(4):360-365.
93. Sood A., Amre D., Midha V., et al. Low hygiene and exposure to infections may be associated with increased risk for ulcerative colitis in a North Indian population. Ann Gastroenterol 2014, 27(3):219-223.
94. Bager P., Simonsen J., Nielsen N.M., et al. Cesarean section and offspring's risk of inflammatory bowel disease: a national cohort study. Inflamm Bowel Dis 2012, 18(5):857-862.
95. Bernstein C.N., Singh S., Graff L.A., et al. A prospective population-based study of triggers of symptomatic flares in IBD. Am J Gastroenterol 2010, 105(9):1994-2002.
96. Sonnenberg A. Occupational distribution of inflammatory bowel disease among German employees. Gut 1990, 31(9):1037-1040.
97. Ananthakrishnan A.N., Long M.D., Martin C.F., et al. Sleep disturbance and risk of active disease in patients with Crohn's disease and ulcerative colitis. Clin Gastroenterol Hepatol 2013, 11(8):965-971.
98. Nguyen G.C., Nugent Z., Shaw S., et al. Outcomes of patients with Crohn's disease improved from 1988 to 2008 and were associated with increased specialist care. Gastroenterology 2011, 141(1):90-97.
99. Ramadas A.V., Gunesh S., Thomas G.A., et al. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010, 59(9):1200-1206.
100. Lakatos P.L., Golovics P.A., David G., et al. Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009. Am J Gastroenterol 2012, 107(4):579-588.
101. Lakatos L., Kiss L.S., David G., et al. Incidence, disease phenotype at diagnosis, and early disease course in inflammatory bowel diseases in Western Hungary, 2002-2006. Inflamm Bowel Dis 2011, 17(12):2558-2565.
102. Burisch J., Pedersen N., Cukovic-Cavka S., et al. Initial disease course and treatment in an inflammatory bowel disease inception cohort in Europe: the ECCO-EpiCom cohort. Inflamm Bowel Dis 2014, 20(1):36-46.
103. Solberg I.C., Vatn M.H., Hoie O., et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007, 5(12):1430-1438.
104. Sands B.E., Arsenault J.E., Rosen M.J., et al. Risk of early surgery for Crohn's disease: implications for early treatment strategies. Am J Gastroenterol 2003, 98(12):2712-2718.
105. Galandiuk S., Kimberling J., Al-Mishlab T.G., et al. Perianal Crohn disease: predictors of need for permanent diversion. Ann Surg 2005, 241(5):796-801. [discussion: 801-2].
106. Hoie O., Wolters F., Riis L., et al. Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol 2007, 102(8):1692-1701.
107. Vester-Andersen M.K., Prosberg M.V., Jess T., et al. Disease course and surgery rates in inflammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapy. Am J Gastroenterol 2014, 109(5):705-714.
108. Vester-Andersen M.K., Vind I., Prosberg M.V., et al. Hospitalisation, surgical and medical recurrence rates in inflammatory bowel disease 2003-2011-a Danish population-based cohort study. J Crohns Colitis 2014, 8(12):1675-1683.
109. Hoie O., Wolters F.L., Riis L., et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology 2007, 132(2):507-515.
110. Henriksen M., Jahnsen J., Lygren I., et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis 2006, 12(7):543-550.
111. Campbell S., Travis S., Jewell D. Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol 2005, 17(1):79-84.
112. Jarnerot G., Hertervig E., Friis-Liby I., et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005, 128(7):1805-1811.
113. Shen B., Fazio V.W., Remzi F.H., et al. Comprehensive evaluation of inflammatory and noninflammatory sequelae of ileal pouch-anal anastomoses. Am J Gastroenterol 2005, 100(1):93-101.
114. Beaugerie L. Inflammatory bowel disease therapies and cancer risk: where are we and where are we going?. Gut 2012, 61(4):476-483.
115. Eaden J.A., Abrams K.R., Mayberry J.F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001, 48(4):526-535.
116. Basseri R.J., Basseri B., Papadakis K.A. Dysplasia and cancer in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2011, 5(1):59-66.
117. Farraye F.A., Odze R.D., Eaden J., et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010, 138(2):738-745.
118. Pedersen N., Duricova D., Elkjaer M., et al. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol 2010, 105(7):1480-1487.
119. Kandiel A., Fraser A.G., Korelitz B.I., et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005, 54(8):1121-1125.
120. Long M.D., Herfarth H.H., Pipkin C.A., et al. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010, 8(3):268-274.
121. Jess T., Frisch M., Simonsen J. Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010. Clin Gastroenterol Hepatol 2013, 11(1):43-48.
122. Wolters F.L., Russel M.G., Sijbrandij J., et al. Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. Gut 2006, 55(4):510-518.
123. Hovde O., Kempski-Monstad I., Smastuen M.C., et al. Mortality and causes of death in Crohn's disease: results from 20 years of follow-up in the IBSEN study. Gut 2014, 63(5):771-775.
124. Romberg-Camps M., Kuiper E., Schouten L., et al. Mortality in inflammatory bowel disease in the Netherlands 1991-2002: results of a population-based study: the IBD South-Limburg cohort. Inflamm Bowel Dis 2010, 16(8):1397-1410.
125. Manninen P., Karvonen A.L., Huhtala H., et al. Mortality in ulcerative colitis and Crohn's disease. A population-based study in Finland. J Crohns Colitis 2012, 6(5):524-528.
126. Jess T., Gamborg M., Munkholm P., et al. Overall and cause-specific mortality in ulcerative colitis: meta-analysis of population-based inception cohort studies. Am J Gastroenterol 2007, 102(3):609-617.
127. Bewtra M., Kaiser L.M., TenHave T., et al. Crohn's disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis. Inflamm Bowel Dis 2013, 19(3):599-613.
128. Jess T., Loftus E.V., Harmsen W.S., et al. Survival and cause specific mortality in patients with inflammatory bowel disease: a long term outcome study in Olmsted County, Minnesota, 1940-2004. Gut 2006, 55(9):1248-1254.
129. Winther K.V., Jess T., Langholz E., et al. Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County. Gastroenterology 2003, 125(6):1576-1582.
130. Hoie O., Schouten L.J., Wolters F.L., et al. Ulcerative colitis: no rise in mortality in a European-wide population based cohort 10 years after diagnosis. Gut 2007, 56(4):497-503.